34 filings
8-K
CLRB
Cellectar Biosciences Inc
19 Dec 19
Cellectar Biosciences to Present at Biotech Showcase 2020
4:03pm
8-K
CLRB
Cellectar Biosciences Inc
16 Dec 19
Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium
4:03pm
8-K
CLRB
Cellectar Biosciences Inc
9 Dec 19
Regulation FD Disclosure
4:01pm
8-K
CLRB
Cellectar Biosciences Inc
4 Dec 19
Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference
12:00am
8-K
CLRB
Cellectar Biosciences Inc
12 Nov 19
Cellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update
8:33am
8-K
iaz695m
30 Oct 19
Cellectar Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
4:01pm
8-K
xbcyb
17 Oct 19
Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
4:09pm
8-K
xwzxunioyu y79s12jcn
15 Oct 19
Cellectar Presents Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology
4:07pm
8-K
25x5zsjhck7c65
8 Oct 19
Cellectar Announces Presentation at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology
4:01pm
8-K
48wcd4q6
30 Sep 19
Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress
4:02pm
8-K
hrrl8
24 Sep 19
Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma
4:25pm
8-K
vb6mmzk9ycbw
16 Sep 19
Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma
4:02pm
8-K
uqks a9vik4y
10 Sep 19
Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019
4:42pm
8-K
4m57ox82 5qo5
4 Sep 19
Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop
4:08pm
8-K
ubwgysf2k3y2o96dcn7k
15 Aug 19
Cellectar Appoints Dov Elefant as Chief Financial Officer
8:30am
8-K
1v3ym2i
14 Aug 19
Regulation FD Disclosure
12:00am
8-K
03hrntlkxo9cce0
12 Aug 19
Cellectar Reports Second Quarter 2019 Financial Results and Provides a Corporate Update
8:30am
8-K
1v00hbk3 ynel
9 Jul 19
Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma
4:05pm
8-K
5dzto2yki0x5kk3a1 k9
14 Jun 19
Departure of Directors or Certain Officers
4:04pm
8-K
cku 705pzfy
21 May 19
Cellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131
4:20pm